Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
43
TECX Quote, Financials, Valuation and Earnings
Last price:
$21.73
Seasonality move
:
-19.4%
Day range:
$20.80 - $21.72
52-week range:
$13.70 - $61.07
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.41x
Volume:
256.6K
Avg. volume:
359.2K
1-year change:
-55.19%
Market cap:
$398.8M
Revenue:
--
EPS (TTM):
-$3.85
Analysts' Opinion
-
Consensus RatingTectonic Therapeutic, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 6 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $78.71, Tectonic Therapeutic, Inc. has an estimated upside of 269.38% from its current price of $21.31.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $64.00 representing 100% downside risk from its current price of $21.31.
Fair Value
-
According to the consensus of 6 analysts, Tectonic Therapeutic, Inc. has 269.38% upside to fair value with a price target of $78.71 per share.
TECX vs. S&P 500
-
Over the past 5 trading days, Tectonic Therapeutic, Inc. has overperformed the S&P 500 by 11.79% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Tectonic Therapeutic, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Tectonic Therapeutic, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Tectonic Therapeutic, Inc. reported revenues of --.
Earnings Growth
-
Tectonic Therapeutic, Inc. has grown year-over-year earnings for 6 quarters straight. In the most recent quarter Tectonic Therapeutic, Inc. reported earnings per share of -$1.02.
Enterprise value:
130.4M
EV / Invested capital:
0.49x
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-2.02x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$1.2M
Return On Assets:
-27.84%
Net Income Margin (TTM):
--
Return On Equity:
-29.43%
Return On Invested Capital:
-29.15%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$4.6M | -$1.4M | -$1.2M | -$424K | -- | |
| Operating Income | -$71.2M | -$53.4M | -$76.5M | -$19.6M | -$21.9M | |
| EBITDA | -$66.6M | -$52M | -- | -$19.2M | -- | |
| Diluted EPS | -$207.22 | -$22.10 | -$3.85 | -$1.20 | -$1.02 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $211.7M | $126.2M | $109.2M | $162.6M | -- | |
| Total Assets | $216.5M | $129.5M | $110.5M | $168.7M | $277M | |
| Current Liabilities | $22.8M | $16.2M | $7.6M | $17.3M | -- | |
| Total Liabilities | $22.9M | $31.4M | $7.7M | $18.4M | -- | |
| Total Equity | $193.6M | $98.1M | $102.9M | $150.4M | $267.5M | |
| Total Debt | -- | $15.2M | $105K | $1.5M | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-06-30 | 2024-06-30 | 2025-06-30 | 2024-06-30 | 2025-06-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$60.6M | -$44.5M | -$64.2M | -$15.1M | -$14.7M | |
| Cash From Investing | -$308K | -$61K | -$128K | -- | $55K | |
| Cash From Financing | -$150K | $212.4M | $166.6M | $179M | -$4.2M | |
| Free Cash Flow | -$60.9M | -$44.6M | -$64.4M | -$15.1M | -$14.7M | |
TECX
Sector
Market Cap
$398.8M
$28.1M
Price % of 52-Week High
34.89%
51.39%
Dividend Yield
0%
0%
Shareholder Yield
-59.42%
-1.49%
1-Year Price Total Return
-55.19%
-17.13%
Beta (5-Year)
1.566
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$19.43
200-day SMA
Buy
Level
$19.93
Bollinger Bands (100)
Buy
Level
15.99 - 22.01
Chaikin Money Flow
Buy
Level
388.9K
20-day SMA
Buy
Level
$19.97
Relative Strength Index (RSI14)
Buy
Level
59.63
ADX Line
Buy
Level
22.41
Williams %R
Sell
Level
-10.4326
50-day SMA
Buy
Level
$18.86
MACD (12, 26)
Buy
Level
5.00
25-day Aroon Oscillator
Buy
Level
16
On Balance Volume
Neutral
Level
2M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (32.3799)
Sell
CA Score
(Annual)
Level (-4.1412)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (7.4244)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (0)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Tectonic Therapeutic, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of therapeutic proteins and antibodies that modulate the activity of G protein-coupled receptors (GPCR). It develops a proprietary technology platform called GEODe to enable the discovery and development of GPCR-targeted biologic medicines. The company was founded by Timothy A. Springer and Andrew Kruse in November 2015 and is headquartered in Watertown, MA.
Stock Forecast FAQ
In the current month, TECX has received 6 Buy ratings 0 Hold ratings, and 0 Sell ratings. The TECX average analyst price target in the past 3 months is $78.71.
-
Where Will Tectonic Therapeutic, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Tectonic Therapeutic, Inc. share price will rise to $78.71 per share over the next 12 months.
-
What Do Analysts Say About Tectonic Therapeutic, Inc.?
Analysts are divided on their view about Tectonic Therapeutic, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Tectonic Therapeutic, Inc. is a Sell and believe this share price will drop from its current level to $64.00.
-
What Is Tectonic Therapeutic, Inc.'s Price Target?
The price target for Tectonic Therapeutic, Inc. over the next 1-year time period is forecast to be $78.71 according to 6 Wall Street analysts, 6 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is TECX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Tectonic Therapeutic, Inc. is a Buy. 6 of 6 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of TECX?
You can purchase shares of Tectonic Therapeutic, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Tectonic Therapeutic, Inc. shares.
-
What Is The Tectonic Therapeutic, Inc. Share Price Today?
Tectonic Therapeutic, Inc. was last trading at $21.73 per share. This represents the most recent stock quote for Tectonic Therapeutic, Inc.. Yesterday, Tectonic Therapeutic, Inc. closed at $21.31 per share.
-
How To Buy Tectonic Therapeutic, Inc. Stock Online?
In order to purchase Tectonic Therapeutic, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get TECX Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
TECX
Sector
P/E ratio
--
23.89x
PEG ratio
--
-0.01x
P/B ratio
1.41x
1.81x
Price / LTM sales
--
1.59x
Growth Metrics
TECX
Sector
Revenue growth
--
4.62%
Earnings growth
15.32%
11.06%
Revenue (5-year growth)
--
6.5%
Earnings forecast
--
-$0.21
Profitability
TECX
Sector
Profitability FY 2024
-$1.6M
$3.6M
Return on invested capital
-29.15%
-31.84%
Return on assets
-27.84%
-27.96%
Return on equity
-29.43%
-37.63%
Earnings Date
Last Earnings Date
Nov
6
Next Earnings Date
Mar
19
Estimated Next Earnings Date
Feb
5
Balance Sheet
TECX
Sector
Total cash
$268.4M
$26.4M
Short term investments
--
$25.7M
Total assets
$152.9M
$76.9M
Long term debt
--
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
85
HUT alert for Dec 24
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Buy
63
GPCR alert for Dec 24
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.
Sell
32
SMX alert for Dec 24
SMX (Security Matters) Plc [SMX] is down 8.94% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
